Objective To perform a meta-analysis of randomized, blinded, multiple sclerosis (MS) clinical
trials, to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies …

Age and the risks of high-efficacy disease modifying drugs i... : Current Opinion in
Neurology Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis …

Objective: To verify the hypothesis of an age-dependent increase of infections and
neoplasms in patients with multiple sclerosis (MS) under disease-modifying treatments …

Multiple sclerosis (MS), an inflammatory demyelinating and neurodegenerative disease of
the central nervous system, usually begins between the ages of 20 and 49 years, though in …

Background: Disease modifying therapy (DMT) efficacy trials make an essential contribution
to the development of evidence-based clinical treatments and practices for people with …

Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease
with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a …

This review updates and extends earlier Consensus Reports related to current basic and
escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature …

Results from registry studies can provide valuable information about the prevalence and
clinical course of different forms of multiple sclerosis (MS). Such studies can also help …

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded
considerably over the last 10 years with the approval of multiple new disease-modifying …

Background: Few studies have analysed long-term effects of immunomodulatory disease
modifying drugs (DMDs). Objective: Assessment of the efficacy of DMDs on long-term …